Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.35 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.35 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | TACR2 | P21452 | 6/20 | 0.34 |
| ▸ | TACR1 | P25103 | 6/20 | 0.34 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1971001 | 0.81 | SLC6A4 (0.37) | LMNATP53MAPTSLC6A4SLC6A2 | |
| SCHEMBL1974696 | 0.81 | PTPRB (0.33) | SLC6A4SLC6A2SLC6A3UTS2R | |
| SCHEMBL1972616 | 0.80 | SLC6A4 (0.35) | LMNATP53MAPTSLC6A4SLC6A2 | |
| SCHEMBL15397635 | 0.76 | LMNA (0.43) | LMNATP53MAPTSLC6A4SLC6A2 | |
| SCHEMBL1970342 | 0.75 | TACR1 (0.42) | TACR2TACR1 | |
| SCHEMBL1969394 | 0.74 | TACR1 (0.44) | SLC6A4SLC6A2SLC6A3TACR1 | |
| SCHEMBL1973935 | 0.74 | TACR1 (0.43) | TACR2TACR1 | |
| SCHEMBL1972983 | 0.73 | TACR1 (0.38) | TACR2TACR1 | |
| SCHEMBL1968593 | 0.73 | TACR2 (0.38) | SLC6A4SLC6A2SLC6A3TACR2TACR1 | |
| SCHEMBL1971145 | 0.72 | PDE5A (0.35) | SLC6A4SLC6A2SLC6A3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| EP-2336105-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | LMNA 1748/4885TP53 4167/4885MAPT 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.